Editas Medicine Q2 net loss narrows to $18.2M; EDIT-401 on track for CTN submission

Editas Medicine, Inc.

Net loss $18.2M ($0.15/sh) vs $53.2M ($0.63/sh) in Q2 2025; collaboration revenue up to $11.9M.
Cash $211.6M as of June 30, 2026, up from $146.6M; cash runway into H2 2028.
EDIT-401 preclinical data shows ~90% mean reduction in LDL-C, Lp(a), ApoB in NHPs; CTN submission planned this month.
Phase 1/2 trial for HeFH to start; data update expected Q1 2027.
Board: Elliott Levy resigned; Patrick Ellinor appointed as independent director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.